Citius Oncology Raises $9mln, Shares Plummet Over 5%

Citius Oncology, a subsidiary of Citius Pharmaceuticals, has entered into a securities purchase agreement with a single institutional investor to purchase 5.14 million shares of common stock for $9 million. The offering was priced at $1.75 per share, which is below the current market price, resulting in a drop of over 5% in Citius Oncology's shares.

Citius Oncology, Inc. (Nasdaq: CTOR), a subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), experienced a significant drop in its stock price following a $9 million securities offering. The company entered into a securities purchase agreement with a single institutional investor to purchase 5.14 million shares of common stock at a price of $1.75 per share. This offering was priced below the current market price, resulting in a drop of over 5% in Citius Oncology's shares .

The securities purchase agreement, which closed on or about September 10, 2025, subject to customary closing conditions, was part of a registered direct offering and a concurrent private placement. The gross proceeds from the offering are estimated to be approximately $9.0 million before deducting placement agent fees and other estimated offering expenses .

Citius Oncology, which focuses on the development and commercialization of innovative targeted oncology therapies, saw its stock price decrease to $1.51 per share, down from the previous close. This offering was made pursuant to a registration statement on Form S-3, which was declared effective by the SEC on September 4, 2025 .

The drop in stock price is likely due to the dilution effect of the offering, as well as the perception of the lower offering price. Investors should monitor the company's upcoming earnings reports and clinical trial results to gauge the potential impact on stock performance .

References:
https://www.benzinga.com/insights/movers/25/09/47455749/12-health-care-stocks-moving-in-tuesdays-intraday-session
https://www.marketbeat.com/instant-alerts/a-mark-precious-metals-amrk-expected-to-announce-earnings-on-tuesday-2025-09-02/
https://www.marketscreener.com/news/citius-oncology-announces-pricing-of-9-0-million-registered-direct-offering-and-concurrent-private-ce7d59dfd188f221